病毒性皮肤病

20101432两种剂量的伐昔洛韦分散片治疗带状疱疹临床疗效对照/剡建平(浙江省新昌人民医院),王玲∥中国皮肤性病学杂志.-2010,24(3).-234~235选择门诊符合诊断标准的带状疱疹患者,分为两组进行随机开放对照试验。治疗组采用伐昔洛韦分散片0.15 g,2次/d,共服10天;对照组采用伐昔洛韦分散片0.3 g,2次/d,共服10天。用药后第3,6和10天观察疗效。结果共入组77例,治疗后第3,6和10天,治疗组的有效率分别是32.5%,42.5%,87.5%;对照组则分别是35.1%,62.2%,89.2%。两组患者治疗指数比较差异无统计学意义。疼痛改变(VAS法分值)比较两组间差     

病毒性皮肤病

20110403元通合剂联合伐昔洛韦治疗带状疱疹疗效观察/冯永芳(武汉市中西医结合医院)∥湖北中医杂志.-2010,32(3).-55治疗组口服元痛合剂(院内制剂,包括龙胆草、柴胡、黄芩、栀子、泽泻、车前子、木通、板蓝根、延胡索、当归、生地等)50mL,盐酸伐昔洛韦分散片0.3g,均2次/d。对照组只服伐昔洛韦0.3g,2次/d。两组均治疗10天后观察疗效。结     

病毒性皮肤病

20111503伐昔洛韦联合干扰素治疗带状疱疹疗效的多因素分析/张优拉(浙江金华市五院皮科),方金仙∥中国麻风皮肤病杂志.-2011,27(5).-364～365共治疗440例带状疱疹,皮损均主要位于躯干部。对照组口服伐昔洛韦0.3g2次/d,10天为1疗程,维生素E0.1g3次/d,共治疗15天。治疗组在对照组治疗基础上肌注干扰素-2b300万U,两天1次,     

病毒性皮肤病

20101774伐昔洛韦治疗带状疱疹临床疗效观察/龚宪军(山东枣庄矿业中心医院皮科)∥中国性科学.-2010,19(6).-37~40140例患者,随机分为两组各70例。试验组予伐昔洛韦0.3g2次/d,对照组阿昔洛韦0.2g5次/d口服,疗程均为10天。结果:止痛、止疱、结痂时间试验组明显快于对照组,痊愈、显效、有效率前者亦明显优于后者。认为伐昔洛韦治疗带状疱疹疗效好,不良反应少,服用方便,安全有效。表2参2(张锦章)20101775窄谱中波紫外线联合伐昔洛韦口服治疗老年性带状疱疹临床观察/李梅(上海奉贤镇塘外卫生院)∥中国中西医结合皮肤性病学杂志.-2010,9(2).-120将患者随机分     

伐昔洛昔联合甘露聚糖肽治疗复发性生殖器疱疹疗效观察

目的观察伐昔洛韦胶囊联合甘露聚糖肽针剂治疗复发性生殖器疱疹的疗效。方法治疗组45例口服伐昔洛韦胶囊0.3g/次,2次/d;甘露聚糖肽针5mg加利多卡因0.5mL局部皮下注射,3日1次,共10次。对照组40例予口服伐昔洛韦胶囊0.3g/次,2次/d。疗程均为1个月。治疗结束,随访1年。结果治疗组复发率22.2%,低于对照组复发率55.0%,无明显的不良反应。结论伐昔洛韦胶囊联合甘露聚糖肽针治疗生殖器疱疹疗效满意。     

盐酸伐昔洛韦治疗带状疱疹临床疗效观察

目的:评价盐酸伐昔洛韦治疗带状疱疹的临床疗效。方法:将入选患者随机分为两组,治疗组患者给予盐酸伐昔洛韦0.3g,每日2次口服;对照组患者给予阿昔洛韦0.2g,每日5次口服。疗程均为10d,并于用药后观察记录临床症状和体征改善情况。结果:盐酸伐昔洛韦的平均止痛、止疱、结痂时间均比阿昔洛韦短,治疗组有效率为91.4%,对照组有效率为54.3%,两组有效率比较,差异有显著性意义(P0.01)。结论:盐酸伐昔洛韦治疗带状疱疹疗效好,不良反应少,是一个安全有效的药物。     

大剂量口服伐昔洛韦片治疗带状疱疹的疗效观察

目的:观察大剂量伐昔洛韦片治疗带状疱疹的临床疗效。方法:将66例带状疱疹患者随机分为治疗组和对照组:治疗组31例,给予伐昔洛韦片1 000 mg口服,每日3次,共7天;对照组35例,给予伐昔洛韦片300 mg口服,每日2次,共10天。用药后第3、5、8、11天观察疗效,皮疹消退后1个月随访后遗神经痛的发生情况。结果:治疗组的止痛时间、止疱时间、皮疹结痂时间均明显短于对照组,后遗神经痛的发生率(6.45%)低于对照组(28.57%),两组比较有明显差异(P<0.05),而不良反应的发生率无统计学差异(分别为19.35%、20.00%,P>0.05)。结论:在带状疱疹早期应用伐昔洛韦1 000 mg口服、每日3次、共7天疗法较伐昔洛韦300 mg口服、每日2次、共10天疗法起效快、疗效好,并能明显减少后遗神经痛的发生率,值得临床推广。     

海特光联合伐昔洛韦治疗带状疱疹疗效观察

目的观察海特光联合伐昔洛韦治疗带状疱疹的临床疗效。方法对照组52例,口服伐昔洛韦0.3,2次/d共7天。治疗组52例,口服药物同对照组,同时予海特光局部照射,1次/d,每次30min,5天为一疗程,用药后第1、3、5、7、14天观察疗效和不良反应。结果治疗组有效率94.23%,对照组有效率70.12%,治疗组在止痛、止疱、结痂时间均明显优于对照组,两组有效率差异有统计学意义(P0.05)。结论海特光联合伐昔洛韦治疗带状疱疹有较好的疗效。     

伐昔洛韦片治疗带状疱疹临床疗效观察

目的:评价伐昔洛韦片(维德思)治疗带状疱疹的临床疗效.方法:将入选患者随机分为两组,实验组患者给予伐昔洛韦片口服,1 g/d,每日3次;对照组患者给予阿昔洛韦片口服,0.2 g/d,每日5次.疗程均为7 d,并于用药后观察记录临床症状和体征改善情况.结果:实验组的平均止痛、止疱、结痂时间均比对照组短,实验组有效率为93.4%,对照组有效率为49.2%,两组有效率比较,差异有显著性意义(P<0.01).实验组1例,对照组4例在治疗过程中出现轻度不良反应.结论:伐昔洛韦片治疗带状疱疹疗效好,不良反应少,是治疗带状疱疹安全有效的药物.     

窄谱中波紫外线联合伐昔洛韦口服治疗老年性带状疱疹临床观察

目的观察窄谱中波紫外线（NB-UVB）联合伐昔洛韦治疗老年性带状疱疹临床疗效。方法将82例老年带状疱疹患者,随机分两组,治疗组41例,局部照射NB-UVB联合伐昔洛韦口服;对照组41例,单纯口服伐昔洛韦,疗程均为10d。结果治疗组疗效明显优于对照组,后遗神经痛发生率低。结论NB-UVB联合伐昔洛韦口服治疗老年性带状疱疹,可以缩短病程,提高疗效,减少后遗神经痛的发生。     

伐昔洛韦联合小牛脾提取物治疗带状疱疹48例疗效评价

目的:评价伐昔洛韦联合小牛脾提取物治疗带状疱疹的疗效和安全性。方法:将95例带状疱疹患者随机分为2组,治疗组(48例)给予伐昔洛韦片和小牛脾提取物注射液;对照组(47例)仅给予伐昔洛韦片,10天后观察疗效。结果:治疗组总有效率为85.42%,对照组总有效率68.09%,治疗组的止疱、结痂、止痛时间和总病程明显缩短。结论:伐昔洛韦联合小牛脾提取物治疗带状疱疹疗效优于单用伐昔洛韦。     

半导体激光联合伐昔洛韦治疗带状疱疹疗效观察

目的观察半导体激光、He—Ne激光联合伐昔洛韦治疗带状疱疹的临床疗效。方法将118例带状疱疹患者分为3组,试验组、对照组1及对照组2。所有患者均给予伐昔洛韦以及维生素B1、维生素B12治疗。试验组和对照组1再分别使用半导体激光和He—Ne激光照射。结果试验组在痊愈率、总有效率及止痛、止疱、结痂时间、后遗神经痛发生率等方面均明显优于对照组。结论半导体激光联合伐昔洛韦治疗带状疱疹疗程短,疗效快,安全性好。     

Amenamevir,a novel helicase–primase inhibitor,for treatment of herpes zoster: A randomized,double‐blind,valaciclovir‐controlled phase 3 study

Amenamevir is a potent helicase–primase inhibitor and a novel class of antiviral agent other than nucleoside compounds, such as aciclovir, valaciclovir and famciclovir. This study is the first randomized, double‐blind, valaciclovir‐controlled phase 3 study to evaluate the efficacy and safety of amenamevir in Japanese patients with herpes zoster when treated within 72 h after onset of rash. A total of 751 patients were randomly assigned to receive either amenamevir 400 mg or 200 mg p.o. once daily or valaciclovir 1000 mg three times daily (daily dose, 3000 mg) for 7 days. The primary efficacy end‐point was the proportion of cessation of new lesion formation by day 4 (“day 4 cessation proportion”). The day 4 cessation proportions for amenamevir 400 and 200 mg and valaciclovir were 81.1% (197/243), 69.6% (172/247) and 75.1% (184/245), respectively. Non‐inferiority of amenamevir 400 mg to valaciclovir was confirmed by a closed testing procedure. Days to cessation of new lesion formation, complete crusting, healing, pain resolution and virus disappearance were evaluated as secondary end‐points. No significant differences were observed in any of the treatment groups. Amenamevir 400 and 200 mg were well tolerated as well as valaciclovir. The proportions of patients who experienced drug‐related adverse events were 10.0% (25/249), 10.7% (27/252) and 12.0% (30/249) with amenamevir 400 and 200 mg and valaciclovir, respectively. In conclusion, amenamevir 400 mg appears to be effective and well tolerated for treatment of herpes zoster in immunocompetent Japanese patients.     

溴夫定治疗带状疱疹的疗效和安全性评价

目的 评价溴夫定125mg每天1次和每天4次治疗带状疱疹的疗效和安全性.方法 多中心、随机、双盲、平行对照临床试验.226例带状疱疹患者分别接受溴夫定125mg每天1次(112例)或每天4次(114例)治疗,疗程7d,再随访3周.结果 新水疱停止出现时间,单次剂量组平均为3.88d,4次剂量组为3.79d,两组比较,差异无统计学意义.水疱完全消退时间、开始结痂时间、全部结痂时间、开始脱痂时间、全部脱痂时间、疼痛开始减轻时间和疼痛完全消失时间两组比较,差异均无统计学意义.单次剂量组有34.5%、4次剂量组有30.4%的患者皮损痊愈后仍存在疱疹相关疼痛.药物相关不良反应发生率分别为5.4%和9.6%.结论 溴夫定125mg每天1次和每天4次治疗带状疱疹同样有效,但单次剂量组更方便、安全.     

Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir

AIM OF THE STUDY: An observational study with valaciclovir was conducted to assess clinical outcome in herpes zoster, especially pain and associated neurological signs and symptoms in relation to a series of demographic and disease characteristics discernible at presentation. The safety and acceptability of valaciclovir for treatment of zoster was assessed in a wide variety of primary care and clinic referral settings. METHODS: In total, 1897 immunocompetent adults with clinically diagnosed, localized acute herpes zoster were enrolled in this international, open-label study of valaciclovir. All subjects received treatment with oral valaciclovir (1000 mg three times daily) for 7 days from entry to the study and were asked to record the presence of zoster-associated pain and abnormal sensations throughout treatment and 6 months' follow-up. They were seen frequently in clinic to verify subjective assessments and for evaluation of rash healing. Safety and tolerability were assessed by adverse event monitoring. RESULTS: Overall, 1191 subjects (63%) were aged > or = 50 years, and 203 (11%) had ophthalmic zoster. Cessation of zoster-associated pain was significantly faster in the younger age group; median times to loss of zoster-associated pain were 23 days and 9 days in the > or = 50 and < 50 years age groups, respectively. Similarly, abnormal sensations resolved significantly more rapidly in the younger subjects; the median duration of abnormal sensations was 31 days in the > or = 50 year olds and 16 days in those aged < 50 years. In cases of ophthalmic zoster, the rate of pain resolution was not different from those with zoster in other dermatomes (median duration of pain 18 vs. 16 days). However, abnormal sensations persisted significantly longer in subjects with ophthalmic zoster than in those with zoster at other sites (47 vs. 22 days). In addition to advancing age, subjects suffering moderate to severe prodromal pain or acute pain during the rash phase were at significantly greater risk of zoster-associated pain and abnormal sensations persisting for longer. Subjects with concomitant neurological disorders were also more likely to develop prolonged abnormal sensations. Valaciclovir treatment was well tolerated, and adverse events were rare and generally mild. CONCLUSION: This study confirmed the prognostic importance of advancing age and the intensity of prodromal or acute pain as risk factors for prolonged zoster-associated pain and persisting abnormal sensations in the affected dermatome. Ophthalmic zoster and pre-existing neurological disorders are also identified as highly significant risk factors for prolonged abnormal sensations in herpes zoster.     

Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older

BACKGROUND: Herpes zoster (shingles) is a common disease caused by a reactivation of the latent varicella-zoster virus (chickenpox), which resides in the dorsal root ganglia. Valacyclovir HCl, the L-valyl ester of acyclovir, is an antiviral drug that is used to accelerate the resolution of the herpes zoster rash and associated pain and reduce the duration of postherpetic neuralgia. OBJECTIVE: To demonstrate the safety and efficacy of oral valacyclovir 1.5 g twice daily (bid) for the treatment of uncomplicated herpes zoster in immunocompetent patients over 18 years of age. The dosing schedule of bid versus three times daily is desirable for enhancing patient compliance and to subsequently reduce the incidence of viral resistance. METHODS: One treatment group of 125 patients was administered oral valacyclovir 1.5 g bid for 7 days. Administration of the first dose occurred within 72 hours after onset of rash. Patients were seen and assessed for cutaneous healing, zoster-associated pain (ZAP), and/or zoster-associated abnormal sensations (ZAAS). Patients under 50 years of age were followed for 4 weeks and patients 50 years of age and older were followed for a total of 24 weeks. Patients >or= 50 years were also asked to record a daily diary on pain and abnormal sensations throughout the 24-week study period. Responses to resource use and quality of life questions were also collected. Safety was monitored by means of routine hematologic and biochemical assessments and reporting of adverse experiences. RESULTS: Data from this study were compared with historical control groups both for three times daily antiviral therapy and for placebo. The results showed that twice-daily dosing was as safe and effective as three times daily dosing for the reduction of ZAP and ZAAS. Adverse-effect profiles were similar between the two different regimens, and both treatment groups showed better outcomes than the historical placebo group. Because it is standard of care to administer antivirals for the treatment of acute herpes zoster, a placebo-controlled trial is not possible, necessitating the use of historical controls. CONCLUSION: Oral valacyclovir 1.5 g bid is safe and effective for the treatment of uncomplicated herpes zoster in immunocompetent patients over 18 years of age. Twice-daily dosing may help increase patient compliance and therefore increase the effectiveness of treatment of the acute herpes zoster rash and the prevention of ZAP.     

壮医药线点灸对带状疱疹患者临床疗效及血清Th细胞因子的影响

目的探讨壮医药线点灸对带状疱疹患者临床疗效及血清Th细胞因子的影响。方法带状疱疹患者80例,随机分成A、B组,40例/组。A组给予口服泛昔洛韦3次/d,0.25 g/次,实施壮医药线点灸,1次/d。B组仅给予口服泛昔洛韦3次/d,0.25 g/次。10d后比较2组患者临床疗效及治疗前后血清IL-2,IL-4和TNF-α水平变化。结果2组临床有效率分别为77.5%、52.5%,差异有统计学意义(P<0.05);2组治疗前血清IL-2,IL-4和TNF-α差异无统计学意义。A组治疗前后血清IL-2,IL-4和TNF-α差异有统计学意义(P<0.05),B组治疗前后血清IL-2,IL-4和TNF-α差异有统计学意义(P<0.05)。2组在治疗后相比,血清IL-2,IL-4和TNF-α差异有统计学意义(P<0.05)。结论壮医药线点灸联合泛昔洛韦治疗带状疱疹能够提高疗效,并能改善患者血清Th细胞因子水平。     

Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.

OBJECTIVE: To compare the efficacy and safety of twice daily valaciclovir with five times daily aciclovir in the treatment of an episode of recurrent genital herpes simplex virus (HSV) infection in immunocompetent individuals. METHODS: 739 patients with a history of recurrent genital HSV infection received either oral valaciclovir (500 mg twice daily) or aciclovir (200 mg five times daily) for 5-days for treatment of their next recurrent episode in a controlled, randomised, double blind trial. Patients self initiated therapy at the first signs and/or symptoms of the HSV recurrence, then were assessed in clinic on five occasions over 7 days, and twice weekly thereafter until lesions had healed. Safety was evaluated through adverse experience reports and haematology and biochemistry monitoring. RESULTS: No significant differences were detected between valaciclovir and aciclovir for the primary endpoint, the duration of all signs and symptoms which included lesion healing and pain/discomfort. The hazard ratio [95% confidence interval] for valaciclovir v aciclovir was 0.93 [0.79, 1.08]. Lesion healing time was similar in each treatment group (hazard ratio valaciclovir v aciclovir 0.96 [0.80, 1.14]). The odds ratio of valaciclovir v aciclovir in preventing the development of vesicular/ulcerative lesions was 1.08 [0.82, 1.42]. Percentages of patients in whom all HSV cultures were negative were similar in the valaciclovir and aciclovir groups at 59% and 54% respectively; for patients having equal to or more than one positive culture result after treatment initiation, cessation of virus shedding was similarly rapid for the two treatments (hazard ratio 0.98 [0.75, 1.27]). The safety profiles of valaciclovir and aciclovir were comparable with adverse experiences being infrequent and generally mild. CONCLUSION: This study has demonstrated that valaciclovir 500 mg twice daily is equivalent in efficacy to aciclovir 200 mg five times daily as episodic treatment of recurrent genital HSV infection. Valaciclovir maintains the established efficacy and safety of aciclovir but offers a much more convenient twice daily dosing regimen.     

右旋酮洛芬氨丁三醇治疗带状疱疹神经痛疗效观察

目的观察右旋酮洛芬氨丁三醇在治疗带状疱疹神经痛中的疗效和安全性。方法将入选的132例带状疱疹患者随机分为试验组(71例)和对照组(61例),试验组口服阿昔洛韦0.2g,5次/d,右旋酮洛芬氨丁三醇25mg,3次/d;对照组口服阿昔洛韦0.2g,5次/d,布洛芬0.3g,3次/d,分别在治疗第3、5和7天时观察疗效及其不良反应。结果右旋酮洛芬氨丁三醇联合阿昔洛韦能明显改善患者的疼痛症状,两组有效率比较,差异无显著性意义(P>0.05)。试验组不良反应发生率为7.46%,对照组为20.33%,两者差异有显著性意义(P<0.05)。结论右旋酮洛芬氨丁三醇联合阿昔洛韦治疗。能有效缓解带状疱疹神经痛,且不良反应率低。